Eldon C. Mayer III, M.B.A. Net Worth

The estimated Net Worth of Eldon C. Iii Mayer is at least $795 Thousand dollars as of 17 March 2023. Mr Mayer owns over 4,395 units of Eiger BioPharmaceuticals Inc stock worth over $96,726 and over the last 8 years he sold EIGR stock worth over $41,443. In addition, he makes $657,153 as Exec. VP & Chief Commercial Officer at Eiger BioPharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr A EIGR stock SEC Form 4 insiders trading

Mr has made over 9 trades of the Eiger BioPharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 4,395 units of EIGR stock worth $4,703 on 17 March 2023.

The largest trade he's ever made was buying 100,000 units of Eiger BioPharmaceuticals Inc stock on 10 September 2018 worth over $326,000. On average, Mr trades about 9,572 units every 67 days since 2016. As of 17 March 2023 he still owns at least 56,073 units of Eiger BioPharmaceuticals Inc stock.

You can see the complete history of Mr Mayer stock trades at the bottom of the page.

Mr. Eldon C. Mayer III, M.B.A. biography

Eldon C. Mayer III, M.B.A. is the Exec. VP & Chief Commercial Officer at Eiger BioPharmaceuticals Inc.

What is the salary of Mr A?

As the Exec. VP & Chief Commercial Officer of Eiger BioPharmaceuticals Inc, the total compensation of Mr A at Eiger BioPharmaceuticals Inc is $657,153. There are 7 executives at Eiger BioPharmaceuticals Inc getting paid more, with David Cory having the highest compensation of $2,871,850.

How old is Mr A?

Mr A is 60, he's been the Exec. VP & Chief Commercial Officer of Eiger BioPharmaceuticals Inc since . There are 3 older and 15 younger executives at Eiger BioPharmaceuticals Inc. The oldest executive at Eiger BioPharmaceuticals Inc is Dr. Colin Hislop, 63, who is the Sr. VP of Clinical & Devel. Operations.

What's Mr A's mailing address?

Eldon's mailing address filed with the SEC is C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO, CA, 94306.

Insiders trading at Eiger BioPharmaceuticals Inc

Over the last 9 years, insiders at Eiger BioPharmaceuticals Inc have traded over $3,017,304 worth of Eiger BioPharmaceuticals Inc stock and bought 780,533 units worth $4,706,203 . The most active insiders traders include Richard A Kayne, Edgar Engleman, and Partners X Lp Inter West Ma.... On average, Eiger BioPharmaceuticals Inc executives and independent directors trade stock every 70 days with the average trade being worth of $47,232. The most recent stock trade was executed by Richard A Kayne on 31 October 2023, trading 278,239 units of EIGR stock currently worth $72,342.

What does Eiger BioPharmaceuticals Inc do?

eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.

Complete history of Mr Mayer stock trades at Eiger BioPharmaceuticals Inc and Rigel Pharmaceuticals

Eiger BioPharmaceuticals Inc executives and stock owners

Eiger BioPharmaceuticals Inc executives and other stock owners filed with the SEC include:

• David Cory,
  President, Chief Executive Officer, Director
• David Apelian,
  Director
• Stephana Patton,
  Chief Compliance Officer, General Counsel, Corporate Secretary
• Sriram Ryali,
  Chief Financial Officer
• David A. Cory M.B.A., R.Ph., R.Ph, MBA,
  Bus. Founder, Pres, CEO & Director
• James Shaffer,
  Chief Business Officer
• David A. Cory R.Ph, MBA,
  Bus. Founder, Pres, CEO & Director
• Eldon C. Mayer III, M.B.A.,
  Exec. VP & Chief Commercial Officer
• Sriram Ryali M.B.A.,
  Chief Financial Officer
• Christine Murray,
  Independent Director
• Thomas Dietz,
  Independent Chairman of the Board
• Amit Sachdev,
  Independent Director
• Evan Loh,
  Independent Director
• Eldon Mayer,
  Executive Vice President, Chief Commercial Officer
• Jeffrey Glenn,
  Independent Director
• Dr. Evan Loh,
  CEO of Paratek Pharmaceuticals & Director
• Dr. Jeffrey S. Glenn,
  Founder, Scientific Advisor & Independent Director
• Dr. Stephana E. Patton J.D., Ph.D.,
  Consultant
• Erik Atkisson,
  Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Dr. Colin Hislop,
  Sr. VP of Clinical & Devel. Operations
• Rich Franco M.B.A.,
  Sr. VP & Progeria Program Lead
• Dr. Ingrid C. Choong,
  Sr. VP of Clinical Devel.
• Charles Bramlage,
  Director
• Edgar Engleman,
  Director
• Joanne Quan,
  Chief Medical Officer
• Eduardo Bruno Martins,
  SVP, Liver and Infectious Dise
• Ventures Vi, Llc Vivo Ventu...,
  
• James H Welch,
  Chief Financial Officer
• Nina S Kjellson,
  Director
• Kim Sablich,
  
• Partners X Lp Inter West Ma...,
  
• Ingrid Choong,
  Chief Business Officer
• Erik Atkisson,
  GC & Chief Compliance Officer
• Lisa Kelly Croswell,
  
• James Vollins,
  General Counsel
• Leen Kawas,
  
• Richard A Kayne,